## Contractor Information

<table>
<thead>
<tr>
<th>CONTRACTOR NAME</th>
<th>CONTRACT TYPE</th>
<th>CONTRACT NUMBER</th>
<th>JURISDICTION</th>
<th>STATES</th>
</tr>
</thead>
<tbody>
<tr>
<td>National Government Services, Inc.</td>
<td>MAC - Part A</td>
<td>06101 - MAC A</td>
<td>J - 06</td>
<td>Illinois</td>
</tr>
<tr>
<td>National Government Services, Inc.</td>
<td>MAC - Part B</td>
<td>06102 - MAC B</td>
<td>J - 06</td>
<td>Illinois</td>
</tr>
<tr>
<td>National Government Services, Inc.</td>
<td>MAC - Part A</td>
<td>06201 - MAC A</td>
<td>J - 06</td>
<td>Minnesota</td>
</tr>
<tr>
<td>National Government Services, Inc.</td>
<td>MAC - Part B</td>
<td>06202 - MAC B</td>
<td>J - 06</td>
<td>Minnesota</td>
</tr>
<tr>
<td>National Government Services, Inc.</td>
<td>MAC - Part A</td>
<td>06301 - MAC A</td>
<td>J - 06</td>
<td>Wisconsin</td>
</tr>
<tr>
<td>National Government Services, Inc.</td>
<td>MAC - Part B</td>
<td>06302 - MAC B</td>
<td>J - 06</td>
<td>Wisconsin</td>
</tr>
<tr>
<td>National Government Services, Inc.</td>
<td>A and B and HHH MAC</td>
<td>13101 - MAC A</td>
<td>J - K</td>
<td>Connecticut</td>
</tr>
<tr>
<td>National Government Services, Inc.</td>
<td>A and B and HHH MAC</td>
<td>13102 - MAC B</td>
<td>J - K</td>
<td>Connecticut</td>
</tr>
<tr>
<td>National Government Services, Inc.</td>
<td>A and B and HHH MAC</td>
<td>13202 - MAC B</td>
<td>J - K</td>
<td>New York - Downstate</td>
</tr>
<tr>
<td>National Government Services, Inc.</td>
<td>A and B and HHH MAC</td>
<td>13282 - MAC B</td>
<td>J - K</td>
<td>New York - Upstate</td>
</tr>
<tr>
<td>National Government Services, Inc.</td>
<td>A and B and HHH MAC</td>
<td>14111 - MAC A</td>
<td>J - K</td>
<td>Maine</td>
</tr>
<tr>
<td>National Government Services, Inc.</td>
<td>A and B and HHH MAC</td>
<td>14112 - MAC B</td>
<td>J - K</td>
<td>Maine</td>
</tr>
<tr>
<td>National Government Services, Inc.</td>
<td>A and B and HHH MAC</td>
<td>14211 - MAC A</td>
<td>J - K</td>
<td>Massachusetts</td>
</tr>
<tr>
<td>National Government Services, Inc.</td>
<td>A and B and HHH MAC</td>
<td>14212 - MAC B</td>
<td>J - K</td>
<td>Massachusetts</td>
</tr>
<tr>
<td>CONTRACTOR NAME</td>
<td>CONTRACT TYPE</td>
<td>CONTRACT NUMBER</td>
<td>JURISDICTION</td>
<td>STATES</td>
</tr>
<tr>
<td>-----------------</td>
<td>---------------</td>
<td>-----------------</td>
<td>--------------</td>
<td>----------</td>
</tr>
<tr>
<td>National Government Services, Inc.</td>
<td>A and B and HHH MAC</td>
<td>14311 - MAC A</td>
<td>J - K</td>
<td>New Hampshire</td>
</tr>
<tr>
<td>National Government Services, Inc.</td>
<td>A and B and HHH MAC</td>
<td>14312 - MAC B</td>
<td>J - K</td>
<td>New Hampshire</td>
</tr>
<tr>
<td>National Government Services, Inc.</td>
<td>A and B and HHH MAC</td>
<td>14411 - MAC A</td>
<td>J - K</td>
<td>Rhode Island</td>
</tr>
<tr>
<td>National Government Services, Inc.</td>
<td>A and B and HHH MAC</td>
<td>14412 - MAC B</td>
<td>J - K</td>
<td>Rhode Island</td>
</tr>
<tr>
<td>National Government Services, Inc.</td>
<td>A and B and HHH MAC</td>
<td>14511 - MAC A</td>
<td>J - K</td>
<td>Vermont</td>
</tr>
<tr>
<td>National Government Services, Inc.</td>
<td>A and B and HHH MAC</td>
<td>14512 - MAC B</td>
<td>J - K</td>
<td>Vermont</td>
</tr>
</tbody>
</table>

**LCD Information**

**Document Information**

**LCD ID**
L39189

**LCD Title**
Mass Spectrometry (MS) Testing in Monoclonal Gammopathy (MG)

**Proposed LCD in Comment Period**
N/A

**Source Proposed LCD**
DL39189

**Original Effective Date**
For services performed on or after 08/01/2022

**Revision Effective Date**
N/A

**Revision Ending Date**
N/A

**Retirement Date**

---

**AMA CPT / ADA CDT / AHA NUBC Copyright Statement**

CPT codes, descriptions and other data only are copyright 2022 American Medical Association. All Rights Reserved. Applicable FARS/HHSARS apply.

Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.

Current Dental Terminology © 2022 American Dental Association. All rights reserved.

Copyright © 2023, the American Hospital Association, Chicago, Illinois. Reproduced with permission. No portion of the American Hospital Association (AHA) copyrighted materials contained within this publication may be copied without the express written consent of the AHA. AHA copyrighted materials including the UB\textsuperscript{04} codes and descriptions may not be removed, copied, or utilized within any software, product, service, solution or derivative work without the written consent of the AHA. If an entity wishes to utilize any AHA materials, please contact the AHA at 312\textsuperscript{ }893\textsuperscript{ }6816.

Making copies or utilizing the content of the UB\textsuperscript{04} Manual, including the codes and/or descriptions, for internal purposes, resale and/or to be used in any product or publication; creating any modified or derivative work of the UB\textsuperscript{04} Manual and/or codes and descriptions; and/or making any commercial use of UB\textsuperscript{04} Manual or any portion thereof, including the codes and/or descriptions, is only authorized with an express license from
Monoclonal gammopathy (MG) is characterized by the proliferation of a single clone of plasma cells which produces monoclonal immunoglobulin protein (M-protein). The M-protein can be an intact immunoglobulin (i.e., containing both heavy and light chains), only light chains (e.g., AL [light chain] amyloidosis), or rarely of heavy chains only (6). The prevalence of M-protein is relatively high, being detected in approximately 3% of the general adult population over 50 years old, and in up to 7% of those seeking medical evaluation (7). MGs represent a spectrum of at least 18 distinct entities, ranging from an asymptomatic limited clonal expansion of plasma cells (e.g., monoclonal gammopathy of undetermined significance (MGUS)), to the potentially life-threatening, such as multiple myeloma (MM) and AL amyloidosis. Therefore, timely diagnosis and treatment to prevent irreversible organ damage is critical. A search for M-protein should be considered in any patient with an elevated total serum protein or otherwise unexplained signs and symptoms suggestive of a plasma cell disorder (6).

CMS National Coverage Policy

Language quoted from Centers for Medicare and Medicaid Services (CMS), National Coverage Determinations (NCDs) and coverage provisions in interpretive manuals is italicized throughout the policy. NCDs and coverage provisions in interpretive manuals are not subject to the Local Coverage Determination (LCD) Review Process (42 CFR 405.860[b] and 42 CFR 426 [Subpart D]). In addition, an administrative law judge may not review an NCD. See Section 1869(f)(1)(A)(i) of the Social Security Act.

Unless otherwise specified, italicized text represents quotation from one or more of the following CMS sources:

Title XVIII of the Social Security Act (SSA):

Section 1862(a)(1)(A) excludes expenses incurred for items or services which are not reasonable and necessary for the diagnosis or treatment of illness or injury or to improve the functioning of a malformed body member.

Section 1833(e) prohibits Medicare payment for any claim which lacks the necessary information to process the claim.

Section 1862(a)(7) excludes routine physical examinations, unless otherwise covered by statute.

CMS Publications:

CMS Publication 100-02, Medicare Benefit Policy Manual, Chapter 15, Section 80.1 – Laboratory services must meet applicable requirements of CLIA

CMS Publication 100-04, Medicare Claims Processing Manual, Chapter 16, Section 40.7 Billing for Noncovered Clinical Laboratory Tests Section and 120.1 Clarification of the Use of the Term “Screening” or “Screen”

CMS Publication 100-04, Medicare Claims Processing Manual, Chapter 30, Section 50 Advance Beneficiary Notice of Noncoverage (ABN)
Indications of Coverage

The use of serum mass spectrometry (MS) in monoclonal gammopathies (MGs), as a potential alternative to serum immunofixation electrophoresis (sIFE), may be considered medically necessary for:

1. Diagnosis: Initial detection of M-protein in patients with suspected monoclonal gammopathy (MG) to confirm a serum protein electrophoresis (SPEP) or serum free light-chain (sFLC) abnormality (1), or
2. Monitoring:
   1. Discrimination between therapeutic monoclonal antibodies and endogenous M-proteins (2), or
   2. Treatment response assessment per guidelines (3-5)

Limitations of Coverage (not covered)

1. Screening
2. Concurrent sIFE testing
3. Urine MS testing

Summary of Evidence

Monoclonal gammopathy (MG) is characterized by the proliferation of a single clone of plasma cells which produces monoclonal immunoglobulin protein (M-protein). The M-protein can be an intact immunoglobulin (i.e., containing both heavy and light chains), only light chains (e.g., AL [light chain] amyloidosis), or rarely of heavy chains only (6).
The prevalence of M-protein is relatively high, being detected in approximately 3% of the general adult population over 50 years old, and in up to 7% of those seeking medical evaluation (7). MGs represent a spectrum of at least 18 distinct entities, ranging from an asymptomatic limited clonal expansion of plasma cells (e.g., monoclonal gammopathy of undetermined significance (MGUS)), to the potentially life-threatening, such as multiple myeloma (MM) and AL amyloidosis. Therefore, timely diagnosis and treatment to prevent irreversible organ damage is critical. A search for M-protein should be considered in any patient with an elevated total serum protein or otherwise unexplained signs and symptoms suggestive of a plasma cell disorder (6).

However, the process for identifying patients with MGs is complex and depends on clinical and diagnostic testing information. Laboratories have developed disparate practices for M-protein detection and quantitative measurement, complicating result harmonization, likely resulting in suboptimal detection of treatable MGs (1). Currently, suspected MGs are initially detected using a combination of three serum-based diagnostic tests: serum protein electrophoresis (SPEP), serum immunofixation electrophoresis (sIFE), and serum measurement of free light-chain (sFLC) (1,5). SPEP testing for M-protein began in the 1930s and has since steadily improved in resolution. The M-protein usually presents as a single narrow peak; in contrast, a broad-based band usually suggests a polyclonal increase in immunoglobulins (usually an infectious, inflammatory, or reactive process). The initial SPEP should be performed in combination with sIFE (uses antibodies against heavy and light chain components) both to confirm monoclonality and determine isotype (the heavy and light chain class, e.g., IgG kappa). M-protein isotype has significance for prognosis and risk-stratification (e.g., progression of MGUS to MM) (8). The sFLC assay is an antibody-based system that can detect low concentrations of monoclonal free light chains (i.e., kappa or lambda) in the serum. FLC quantification is the most analytically sensitive blood-based method commercially available to diagnose and monitor patients with MGs, and is sometimes the only indication of a MG. Assessing changes in M-protein levels helps track disease progression and response to treatment (5).

Other emerging laboratory procedures to detect M-proteins include immunosubtraction (ISUB), mass spectrometry (MS), and heavy/light chain (HLC) isotype quantitative measurement. The MS method combines nanobody enrichment of immunoglobulins with matrix-assisted laser desorption/ionization time of flight mass spectrometry (MALDITOF- MS) (also termed MASS-FIX, Mayo Medical Laboratories). The idea behind MS is that molecular mass can be used instead of electrophoretic patterns to identify and quantify the M-protein since each light and heavy chain has a unique amino acid sequence, and thus a unique molecular mass whose increased concentration could be distinguished from the normal polyclonal background (9). In addition to detection, MS might be able to isotype the M-protein because each immunoglobulin has a constant region with an amino acid sequence unique to each isotype. The multiple charged light and heavy chain ions are converted to their molecular masses, and reconstructed peak area calculations for light chains are used for quantification. Thus, in theory, the MASS-FIX assay uses the unique molecular mass signatures of the different Ig isotypes to generate mass spectra from which M-proteins could be identified, isotyped, and quantified.

A 2016 validation study found comparable analytic sensitivity of MASS-FIX with SPEP and IFE (10). MASS-FIX detected all M-proteins that were detectable by urine or serum protein electrophoresis. In serial dilution studies, MASS-FIX was more analytically sensitive than IFE (identified an M-protein in a higher percentage of samples at every dilution), and where they agreed provided the same primary isotype information for 98% of serum M-proteins (n = 152) and 95% of urine M-proteins (n = 55). A subsequent prospective study of paired serum and urine samples from 257 patients confirmed comparable sensitivity with serum/urine PEP/IFE and sFLC when serum and urine MASS-FIX results were combined (7). A more recent study of 226 patients diagnosed with MGUS or related gammopathy, considered negative for MGUS by protein electrophoresis and sFLC assay, found that M-protein could be detected at baseline in only 24 patients (10.6%) by IFE compared with 113 patients (50%) by MALDI-TOF mass spectrometry (11). IFE cannot distinguish if two bands of the same isotype represent biclonal proteins or M-proteins with some other feature. In a study of 81 serum samples with multiple IFE bands of the same isotype, MASS-FIX was able to characterize them as monoclonal or biclonal (12). In a study of 127 patient sera with abnormal FLC ratios, 43% of monoclonal proteins were confirmed by IFE, 57% by MALDI-TOF MS without FLC enrichment, and 87% with FLC enrichment MALDI-TOF MS (13). The authors conclude that FLC immunoenrichment coupled to MALDI-TOF MS
enables direct detection of mFLCs, significantly increasing the confirmation of abnormal serum FLC ratios (a more indirect methodology), thus improving verification of disease in patients with light chain plasma cell disorders.

Other areas of potential utility include distinguishing endogenous M-proteins from therapeutic monoclonal antibodies; daratumumab, one therapeutic IgG kappa monoclonal antibody, can cause a false positive interference on both SPEP and sIFE, two assays routinely used to monitor a patient’s disease status and response to therapy (14). A study of 31 patients receiving daratumumab with a history of IgG kappa MG found that MASS-FIX could distinguish daratumumab from M-proteins in 26 out of 31 serum samples (84%) versus 14 out of 31 samples (45%) by sIFE (2). Another study of 311 AL amyloidosis patients showed that MASS-FIX can distinguish a subset with light chain glycosylation, providing a potential path to earlier AL amyloidosis diagnosis (15). Automation and integrated software may allow implementation of serum MASS-FIX in a high-throughput clinical laboratory (16).

Analysis of Evidence (Rationale for Determination)

Combined use of SPEP, sIFE, and sFLC is effective in the initial assessment of MG and is recommended in the International Myeloma Working Group (IMWG) guideline for the evaluation of MM and related disorders (17,18). The Myeloma Canada Research Network Consensus Guidelines Consortium and the European Myeloma Network make similar recommendations (19,20).

A just released collaborative guideline from the College of American Pathologists (CAP), the American Association for Clinical Chemistry (AACC), and the American Society for Clinical Pathology (ASCP) recommends that clinicians “should order both SPEP and sFLC for the initial detection of M-protein in all patients with suspected MG” (strong strength of recommendation, evidence strength moderate) (1). To confirm a SPEP abnormality, the guideline recommends a “sIFE or alternative method with similar sensitivity” (strong strength of recommendation, evidence strength moderate). To confirm a sFLC ratio abnormality, the guideline identically recommends a “sIFE or alternative method with similar sensitivity” (conditional recommendation, evidence strength low). That an “alternative method” might include MASS-FIX is supported by the statement that “a new technique involving immunoenrichment followed by matrix-assisted laser desorption/ ionization time-of-flight mass spectrometry (MASS-FIX) has been shown to be a highly sensitive, specific, and cost-effective method comparable to sIFE to detect and identify M-proteins”. However, the guidelines specifically recommend against MS for screening.

UpToDate refers to MS for analyzing monoclonal proteins as “investigational” and “not a standard part of the evaluation of M-proteins in most centers” (6), but finds utility in the setting of AL amyloidosis, noting that to distinguish AL amyloidosis from other forms of amyloidosis “MS is the preferred method since immunohistochemistry and immunofluorescence have a greater risk of false positive and false negative results” (21). It is not mentioned for other MGs (22-24).

NCCN guidelines also recommend amyloid tissue subtyping with MS in the setting of AL amyloidosis “to confirm that the amyloid deposits are composed of light chains.” NCCN recommends MS “only if clinically indicated such as in cases where two potential amyloid precursor proteins are present including patients with monoclonal gammopathies who are African-American or elderly men, or who have dominant peripheral or autonomic neuropathy, family histories of amyloidosis, or coexisting inflammatory disorders” (4). Something similar is noted in the NCCN guideline on Waldenstrom Macroglobulinemia (3). No mention is made of MS in the NCCN MM guideline (5).

In summary, the use of MALDI-TOF MS to detect and characterize MGs is a novel application of well-established technology for detection of proteins, now applied to a well-established clinical indication (e.g., detection of M-proteins to characterize MGs). The MASS-FIX assay is a well validated, characterized, and published application of

Created on 10/05/2023. Page 6 of 9
this technology in this context. Therefore, NGS considers serum MS use in MG as a possible alternative to sIFE in confirming a SPEP or sFLC abnormality, largely in concordance with the CAP/AACC/ASCP collaborative guideline. Serum MS may also provide advantages in distinguishing between therapeutic and endogenous M-proteins. While published studies and guidelines on MS primarily focus on initial diagnosis, since sIFE also figures prominently in MG monitoring guidelines, it seems logical to also cover serum MS as a sIFE alternative in that setting. MS for screening for MGs is not covered.

---

**General Information**

**Associated Information**

N/A

**Sources of Information**

N/A

**Bibliography**

14. McCudden CR, Jacobs JFM, Keren D, Caillon H, Dejoie T, Andersen K. Recognition and management of


Revision History Information
N/A

Associated Documents
Attachments
N/A

Related Local Coverage Documents
Articles
A58921 - Billing and Coding: Mass Spectrometry (MS) Testing in Monoclonal Gammopathy (MG)
A59078 - Response to Comments: Mass Spectrometry (MS) Testing in Monoclonal Gammopathy (MG)
Related National Coverage Documents
N/A

Public Versions

<table>
<thead>
<tr>
<th>UPDATED ON</th>
<th>EFFECTIVE DATES</th>
<th>STATUS</th>
</tr>
</thead>
<tbody>
<tr>
<td>06/06/2022</td>
<td>08/01/2022 - N/A</td>
<td>Currently in Effect (This Version)</td>
</tr>
</tbody>
</table>

Keywords
N/A